Stoke Therapeutics plans $75M public offering on heels of Dravet trial results - Boston Business...

Published on 27 Mar 2024 on The Business Journals

With shares of Stoke Therapeutics Inc. trading at its highest level since October 2022, the biotech...

Read the rest of the article

Start tracking your investments with Statfolio

On Tuesday, Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to...

Benzinga · via Yahoo Finance 18 Feb 2025

Stoke will receive $165 million upfront and may get up to $385 million in milestone payments.

Market Watch 18 Feb 2025

Have a confidential tip for our reporters? Biogen Inc. has agreed to pay as much as $550 million ...

Bloomberg 18 Feb 2025

Biogen Inc. is making good on its promise to focus on “external opportunities,” this time with a ...

The Business Journals 18 Feb 2025

For Immediate Release Chicago, IL – December 26, 2024 – Zacks.com announces the list of stocks...

Zacks · via Yahoo Finance 27 Dec 2024

We recently published a list of 10 Small Cap Stocks with High Potential. In this article, we are...

Insider Monkey · via Yahoo Finance 9 Oct 2024

On May 20, 2024, Edward M. Kaye, MD, Chief Executive Officer of Stoke Therapeutics Inc (NASDAQ:ST...

GuruFocus.com via Yahoo Finance 23 May 2024

Revenue: Reported $4.2 million for Q1 2024, up from $5.2 million in Q1 2023, exceeding the estima...

GuruFocus.com via Yahoo Finance 8 May 2024

With shares of Stoke Therapeutics Inc. trading at its highest level since October 2022, the biote...

The Business Journals 27 Mar 2024

Stoke Therapeutics, Inc. STOK reported encouraging new data from two phase I/IIa studies and two ...

Zacks via Yahoo Finance 27 Mar 2024